Sodium Butyrate Enhances Chemotherapy Sensitivity in Pancreatic Cancer Cells

Strategic Insights -

Scientists investigating the use of the histone deacetylase inhibitor, sodium butyrate (NaB), as a potential treatment for pancreatic cancer have made a significant discovery. The research, published in Current Therapeutic Research - Clinical and Experimental, found that NaB not only induces the expression of the tumor-suppressor gene p53 but also enhances the sensitivity of pancreatic cancer cells to chemotherapy drugs.

This in vitro study used five human pancreatic carcinoma cell lines and found that the use of 1 mM NaB induced histone acetylation and p53 expression in two of the cell lines, SW-1990 and JHP-1. Additionally, the researchers observed a higher frequency of apoptosis in NaB-treated cells compared to control cells. The study also found that NaB treatment significantly enhanced the sensitivity of these cells to certain chemotherapy drugs, including cisplatin, fluorouracil, and SN-38.

Key Takeaways:

  • Sodium butyrate (NaB) induces the expression of the tumor-suppressor gene p53 in pancreatic cancer cells.
  • NaB treatment enhances the sensitivity of pancreatic cancer cells to certain chemotherapy drugs, including cisplatin, fluorouracil, and SN-38.
  • The use of NaB in combination with chemotherapy drugs may be a potential new treatment strategy for pancreatic cancer.
  • The researchers observed a higher frequency of apoptosis in NaB-treated cells compared to control cells.
  • The study used five human pancreatic carcinoma cell lines, including SW-1990, BxPC-3, PANC-1, MIA PaCa-2, and JHP-1.
  • The researchers found that NaB treatment significantly enhanced the sensitivity of SW-1990 and JHP-1 cells to cisplatin (P = 0.021), fluorouracil (P = 0.046), and SN-38 (P = 0.039).

Statistics:

  • 5 human pancreatic carcinoma cell lines were used in the study.
  • 2 cell lines (SW-1990 and JHP-1) lacked p53 expression and were investigated further.
  • 1 mM NaB was found to induce histone acetylation and p53 expression in SW-1990 and JHP-1 cells (P = 0.01 and P = 0.018, respectively).
  • NaB treatment significantly enhanced the sensitivity of SW-1990 and JHP-1 cells to cisplatin (P = 0.021), fluorouracil (P = 0.046), and SN-38 (P = 0.039).

Sources:

  • Current Therapeutic Research - Clinical and Experimental, "Effects of a Histone Deacetylase Inhibitor, Sodium Butyrate, on 53-kDa Protein Expression and Sensitivity to Anticancer Drugs of Pancreatic Cancer Cells."
  • NewsRx.com, "Sodium Butyrate Enhances Chemotherapy Sensitivity in Pancreatic Cancer Cells."